FLPIM
PVLA

F.L. Putnam Investment Management’s Palvella Therapeutics PVLA Stock Holding History

F.L. Putnam Investment Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-166
Closed -$74K – 234
2018
Q3 		$74K Hold
166
– – 0.01% 214
2018
Q2 		$67K Hold
166
– – 0.01% 211
2018
Q1 		$91K Hold
166
– – 0.01% 235
2017
Q4 		$100K Hold
166
– – 0.01% 218
2017
Q3 		$77K Buy
+166
New +$70.9K 0.01% 222

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

F.L. Putnam Investment Management's PVLA Position: Q4 2018 in Review

F.L. Putnam Investment Management sold out of Palvella Therapeutics (PVLA) in Q4 2018, closing a stake of 166 shares — an estimated $74K sold.

F.L. Putnam Investment Management first reported a position in PVLA in Q3 2017 and held it in 5 quarters. The position peaked at $100K in Q4 2017. 98 funds tracked by Wall St. Rank hold PVLA as of Q4 2018.

  • F.L. Putnam Investment Management reported no remaining Palvella Therapeutics position as of Q4 2018 after selling out during the quarter.
  • F.L. Putnam Investment Management sold 166 Palvella Therapeutics shares in Q4 2018, an estimated $74K.
  • F.L. Putnam Investment Management first reported a position in Palvella Therapeutics in Q3 2017 and held it in 5 quarters.
  • F.L. Putnam Investment Management's Palvella Therapeutics position peaked at $100K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2018.

Based on F.L. Putnam Investment Management's 13F filing for Q4 2018, filed 22 Feb 2019.